SANGAMO THERAPEUTICS, INC (41)
Browse by Contract Category
Contracts
-
Amended and Restated 2018 Equity Incentive Plan of Sangamo Therapeutics, Inc
(Filed With SEC on May 25, 2022)
-
Amended and Restated Office and Laboratory Lease between the Company and Point Richmond R&D Associates II, LLC, dated October 18, 2021
(Filed With SEC on February 24, 2022)
-
Letter Agreement between the Company and David Mark McClung dated November 1, 2021
(Filed With SEC on February 24, 2022)
-
Collaboration and License
(Filed With SEC on November 4, 2020)
-
Stock Purchase Agreement between the Company and Biogen MA, Inc., dated February 26, 2020
(Filed With SEC on May 11, 2020)
-
Letter Agreement between the Company and
(Filed With SEC on November 4, 2021)
-
Letter Agreement between the Company and
(Filed With SEC on August 5, 2021)
-
Letter Agreement between the Company and
(Filed With SEC on May 4, 2021)
-
Letter Agreement between the Company and
(Filed With SEC on May 4, 2021)
-
Ninth Amendment to Triple Net Laboratory Lease
(Filed With SEC on May 4, 2021)
-
Description of
(Filed With SEC on February 24, 2021)
-
Letter Agreement dated as of January 22, 2021 between Sangamo Therapeutics, Inc. and Sung Lee
(Filed With SEC on January 28, 2021)
-
Amendment No. 2 to Research Collaboration and License Agreement between the Company and Pfizer Inc., dated July 21, 2020
(Filed With SEC on November 4, 2020)
-
Employment Agreement between the Company and Mark McClung effective as of April 13, 2020
(Filed With SEC on August 5, 2020)
-
Eighth Amendment to the Triple Net Laboratory Lease Agreement, dated May 29, 2020, between the Registrant and Point Richmond R&D Associates II, LLC
(Filed With SEC on August 5, 2020)
-
Seventh Amendment to the Triple Net Laboratory Lease Agreement, dated May 2
(Filed With SEC on August 5, 2020)
-
Letter Agreement
(Filed With SEC on August 5, 2020)
-
Open Market Sale Agreement, dated August 5, 2020, between Sangamo Therapeutics, Inc. and Jefferies LLC
(Filed With SEC on August 5, 2020)
-
Amended and Restated 2018 Equity Incentive Plan of Sangamo Therapeutics, Inc
(Filed With SEC on May 22, 2020)
-
Form of Indemnity Agreement
(Filed With SEC on May 11, 2020)
-
Collaboration and License Agreement among the Company, Biogen MA, Inc. and Biogen International GmbH, dated February 26, 2020
(Filed With SEC on May 11, 2020)
-
Employment Agreement between the Company and Rolf Andrew (Andy) Ramelmeier effective as of November 1, 2017
(Filed With SEC on February 28, 2020)
-
Letter Amendment, dated December 17, 2019, to the Collaboration and License Agreement between the Company and Pfizer Inc., dated May 10, 2017
(Filed With SEC on February 28, 2020)
-
Employment Agreement between the Company and Gary Loeb effective as of June 6, 2019
(Filed With SEC on February 28, 2020)
-
Employment Agreement between the Company and Sung Lee effective as of October 31, 2019
(Filed With SEC on February 28, 2020)
-
Description of Securities of the Company
(Filed With SEC on February 28, 2020)
-
Amended and Restated Collaboration and License Agreement between the Company and Kite Pharma, Inc., dated as of September 11, 2019
(Filed With SEC on November 6, 2019)
-
Amendment No. 1 to Research Collaboration and License Agreement between the Company and Pfizer., dated December 27, 2017, dated as of March 21, 2019
(Filed With SEC on May 8, 2019)
-
Underwriting Agreement, dated April 4, 2019, by and between Sangamo Therapeutics, Inc. and Cowen and Company, LLC, Wells Fargo Securities, LLC and Barclays Capital Inc., as...
(Filed With SEC on April 4, 2019)
-
2018 Equity Incentive Plan French Restricted Stock Unit Award Sub-Plan (the French RSU Sub-Plan)
(Filed With SEC on March 1, 2019)
-
First Amendment to Lease Agreement between the Company and Marina Boulevard Property, LLC dated January 1, 2019
(Filed With SEC on March 1, 2019)
-
Fifth Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&D Associates II, LLC, dated July 10, 2017
(Filed With SEC on March 1, 2019)
-
Fourth Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&D Associates II, LLC, dated June 10, 2016
(Filed With SEC on March 1, 2019)
-
Employment Agreement between the Company and Adrian Woolfson, effective January 21 2019
(Filed With SEC on March 1, 2019)
-
Employment Agreement between the Company and Stphane Boissel, effective October 1, 2018
(Filed With SEC on March 1, 2019)
-
Employment Agreement between the Company and Heather D. Turner, effective February 12, 2018
(Filed With SEC on March 1, 2019)
-
Amended and Restated Severance Plan
(Filed With SEC on March 1, 2019)
-
Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Award Agreement (French employees) under the 2018 Plan and the French RSU Sub-Plan
(Filed With SEC on March 1, 2019)
-
Form of Stock Option Agreement (French Employees) under the 2018 Plan and the French Options Sub-Plan
(Filed With SEC on March 1, 2019)
-
Form of Stock Option Grant Notice (French employees) under the 2018 Plan and the French Options Sub-Plan
(Filed With SEC on March 1, 2019)
-
2018 Equity Incentive Plan French Stock-Options Sub-Plan (the French Options Sub-Plan)
(Filed With SEC on March 1, 2019)
